Literature DB >> 15162380

Establishment and characterization of a primary androgen-responsive African-American prostate cancer cell line, E006AA.

Shahriar Koochekpour1, Grace A Maresh, Adrienne Katner, Kitani Parker-Johnson, Tae-Jin Lee, Francine E Hebert, Yuan S Kao, John Skinner, Walter Rayford.   

Abstract

BACKGROUND: Establishment of human prostate cancer cell lines is essential to advance our understanding of complex processes associated with the initiation and progression of the disease. In the present study, we report the establishment of a primary African-American prostate cancer cell line (E006AA) as well as its associated stromal cells (S006AA).
METHODS: E006AA cell line was established as a spontaneously immortalized cells from a patient with a clinically localized prostate cancer. Extensive characterization of the cells was accomplished using androgen-dependent growth and sensitivity assays, Western analyses, RT-PCR/real-time PCR, cytogenetic analyses, and tumorigenicity in nude mice.
RESULTS: E006AA cell line shows androgen-dependent growth, expresses PSA and the androgen receptor (AR) with 26 CAG repeats in exon 1 of AR. Cytogenetic analyses revealed a hypertriploid karyotype with additional numerical gains in chromosomes 5, 6, 8, 10, 17, 20, 21 and a marker chromosome of unknown origin as well as structural abnormalities in chromosomes 4, 5, 8, 9, 11-14, 18, and 20. This cell line is not tumorigenic in nude mice. S006AA cell line, isolated from the same tumor specimen, also expresses AR and shows the morphological characteristics of smooth muscle cells of prostatic stroma.
CONCLUSIONS: These cell lines are the first available primary epithelial and stromal cells derived from an African-American patient with organ-confined prostate cancer and in conjunction with other established cell lines, could provide an in vitro model system to investigate early transforming events in prostate cancer. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15162380     DOI: 10.1002/pros.20053

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  32 in total

1.  Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells.

Authors:  Ivan V Litvinov; Donald J Vander Griend; Yi Xu; Lizamma Antony; Susan L Dalrymple; John T Isaacs
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

2.  Establishment and characterization of a pair of non-malignant and malignant tumor derived cell lines from an African American prostate cancer patient.

Authors:  Shaniece Theodore; Starlette Sharp; Jianjun Zhou; Timothy Turner; Hongzhen Li; Jun Miki; Youngmi Ji; Vyomesh Patel; Clayton Yates; Johng S Rhim
Journal:  Int J Oncol       Date:  2010-12       Impact factor: 5.650

3.  The identification of a novel antibody for CD133 using human antibody phage display.

Authors:  Paige M Glumac; Colleen L Forster; Hong Zhou; Paari Murugan; Shilpa Gupta; Aaron M LeBeau
Journal:  Prostate       Date:  2018-05-22       Impact factor: 4.104

4.  MiRNA 26a expression in a novel panel of African American prostate cancer cell lines.

Authors:  Shaniece C Theodore; Johng S Rhim; Timothy Turner; Clayton Yates
Journal:  Ethn Dis       Date:  2010       Impact factor: 1.847

5.  ROBO1, a tumor suppressor and critical molecular barrier for localized tumor cells to acquire invasive phenotype: study in African-American and Caucasian prostate cancer models.

Authors:  Aijaz Parray; Hifzur R Siddique; Jacquelyn K Kuriger; Shrawan K Mishra; Johng S Rhim; Heather H Nelson; Hiroyuki Aburatani; Badrinath R Konety; Shahriar Koochekpour; Mohammad Saleem
Journal:  Int J Cancer       Date:  2014-04-29       Impact factor: 7.396

6.  Combination therapy induces unfolded protein response and cytoskeletal rearrangement leading to mitochondrial apoptosis in prostate cancer.

Authors:  Sandeep Kumar; Ajay K Chaudhary; Rahul Kumar; Jordan O'Malley; Anna Dubrovska; Xinjiang Wang; Neelu Yadav; David W Goodrich; Dhyan Chandra
Journal:  Mol Oncol       Date:  2016-03-31       Impact factor: 6.603

7.  Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer.

Authors:  John T Isaacs; Jason M D'Antonio; Shuangling Chen; Lizamma Antony; Susan P Dalrymple; Georges H Ndikuyeze; Jun Luo; Samuel R Denmeade
Journal:  Prostate       Date:  2012-03-06       Impact factor: 4.104

8.  Novel role of Giα2 in cell migration: Downstream of PI3-kinase-AKT and Rac1 in prostate cancer cells.

Authors:  Silvia Caggia; HimaBindu Chunduri; Ana C Millena; Jonathan N Perkins; Smrruthi V Venugopal; BaoHan T Vo; Chunliang Li; Yaping Tu; Shafiq A Khan
Journal:  J Cell Physiol       Date:  2018-08-04       Impact factor: 6.384

9.  Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer.

Authors:  Wennuan Liu; Chunmei Carol Xie; Yi Zhu; Tao Li; Jishan Sun; Yu Cheng; Charles M Ewing; Sue Dalrymple; Aubrey R Turner; Jielin Sun; John T Isaacs; Bao-Li Chang; Siqun Lilly Zheng; William B Isaacs; Jianfeng Xu
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

10.  Ericifolin: a novel antitumor compound from allspice that silences androgen receptor in prostate cancer.

Authors:  Nagarajarao Shamaladevi; Dominic A Lyn; Khaled A Shaaban; Lei Zhang; Susana Villate; Jürgen Rohr; Bal L Lokeshwar
Journal:  Carcinogenesis       Date:  2013-04-08       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.